EPCAM and neoplasm: Genetic deletion of HLA class I cell surface molecules augmented ADCP by anti-epithelial cell adhesion molecule (EpCAM) or anti-epidermal growth factor receptor (EGFR) antibodies, suggesting that the HLA class I:LILRB1 axis may compromise the therapeutic efficacy of tumor targeting antibodies.